适体市场规模、份额、成长分析（按类型、应用和地区）-产业预测，2024-2031

2022年全球适配体市场规模将为1.55亿美元，从2023年的1.8259亿美元成长到2031年的6.7708亿美元，预计在预测期内（2024-2031年）将以17.80的复合年增长率。

适体因其在生产、精製和标靶药物递送方面的最新进展而引起了研究人员的极大兴趣。与传统抗体相比，这些优点包括分子尺寸较小、免疫抗原性较低、製造成本较低、副作用较少。这些特性可能有助于创新适配体的开发，并成为市场开拓的驱动力。儘管进行了广泛的研究，但目前还没有针对各种基因突变引起的感染疾病的高效治疗方法。然而，基于 SELEX 技术的诊断套件和检测方法已显示出生产高亲和性中和剂的前景。这一市场开拓预计将透过采用新的诊断试剂套件带来市场成长。适配体是利用DNA适配体技术开发的第二代诊断工具。这些套件具有成本效益，是化学合成的，并且在诊断中越来越受欢迎。例如，2022 年 3 月，Soma Logic 宣布将采用 SomaScan Assay 分析 30,000 个样本中的 2.1 亿个蛋白质测量结果，用于欧洲癌症与营养前瞻性调查 (EPIC) 研究。这种方法旨在增强疾病预测，特别是癌症，并支持市场扩张。基于适体的诊断解决方案因其尺寸小、特异性高、选择性良好以及在细胞层面检测疾病方面的有效性而受到诊断和病理实验室的青睐。根据英国癌症研究中心估计，到 2040 年，预计将有约 2,750 万人被诊断出患有癌症，这增加了对先进诊断技术的需求。

目录

介绍

• 研究目的
• 定义
• 市场范围

调查方法

• 资讯采购
• 次要/一级资讯来源
• 市场规模预测
• 市场假设与限制

执行摘要

• 市场概况展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 技术分析
• 价值链分析
• 专利分析

适体市场：依类型

• 市场概况
• DNA适体
• XNA适体
• RNA适体

适体市场：依技术分类

• 市场概况
• SELEX
• 其他技术

适体市场：依应用分类

• 市场概况
• 治疗药物开发
• 研究与开发
• 诊断
• 其他用途

适体市场：依最终用户划分

• 市场概况
• 製药和生物技术公司
• 学术/政府研究院
• 药品委外研发机构
• 其他最终用户

适体市场规模：按地区划分

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• Aptamer Group（UK）
• Raptamer Discovery Group（US）
• omalogic, Inc.（US）
• Aptamer Sciences, Inc.（US）
• Aptagen, LLC（US）
• Maravai Lifesciences（US）
• Kaneka Corporation（Japan）
• Neoventures Biotechnology Inc.（Canada）
• Aptus Biotech（Spain）
• Base Pair Biotechnologies（US）
• Amsbio（UK）
• Novaptech（France）
• Bio-Techne（US）
• Aptitude Medical Systems（US）
• Raybiotech, Inc.（US）
• Alpha Diagnostic International, Inc.（US）
• Creative Biolabs（US）
• Creative Biogene（US）
• Vivonics Inc.（US）
• Iba Lifesciences GmbH（Germany）
• Aptabharat Innovations Pvt. Ltd（India）
• Profacgen（US）
• Mediven（Germany）
• Pure Biologics SA（Poland）
• Oak Biosciences, Inc.（US）

Global Aptamers Market size was valued at USD 155 million in 2022 and is poised to grow from USD 182.59 million in 2023 to USD 677.08 million by 2031, growing at a CAGR of 17.80% during the forecast period (2024-2031).

Aptamers have gained significant interest from researchers due to their distinct advantages in recent advancements related to production, purification, and targeted drug delivery. These benefits include their small molecular size, low immunogenicity, reduced manufacturing costs, and fewer side effects compared to traditional antibodies. These attributes contribute to the potential development of innovative aptamers, which may drive market growth. Despite extensive research, there are currently no highly effective treatments for infections due to various genetic variations. However, SELEX technology-based diagnostic kits and assays have shown promise in generating high-affinity neutralizers. This development is expected to stimulate market growth with the introduction of new diagnostic kits. Aptamers represent a second-generation diagnostic tool developed using DNA aptamer technology. These kits are cost-effective, chemically synthesized, and increasingly popular in diagnostics. For instance, in March 2022, Soma Logic announced that it was employing the SomaScan Assay to analyze 210 million protein measurements from 30,000 samples for the European Prospective Investigation into Cancer and Nutrition (EPIC) study. This approach aims to enhance disease prediction, particularly cancer, thereby supporting market expansion. Aptamer-based diagnostic solutions are favored by diagnostic and pathology labs due to their small size, high specificity, selectivity, and effectiveness in cellular-level disease detection. According to Cancer Research UK, it is estimated that around 27.5 million people will receive a cancer diagnosis by 2040, underscoring the growing demand for advanced diagnostic technologies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Aptamers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Aptamers Market Segmental Analysis

Global Aptamers Market is segmented by Type, Technology, Application, End User, and region. Based on Type, the market is segmented into DNA Aptamers, XNA Aptamers, and RNA Aptamers. Based on Technology, the market is segmented into SELEX, Other Technologies. Based on Application, the market is segmented into Therapeutics Development, Research & Development, Diagnostics, Other Applications. Based on End User, the market is segmented into Pharmaceutical & Biotechnology Companies, Academic & Government Research Institutes, Contract Research Organizations, Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global Aptamers Market

The increasing demand for personalized medicine is driving the growth of the global aptamers market. Aptamers, with their ability to bind specifically to target molecules such as proteins, peptides, and small compounds, are becoming essential in the development of targeted therapies and precision medicine. Their high specificity, low immunogenicity, and customizable nature make them ideal for personalized treatment strategies. Additionally, aptamers offer significant advantages over traditional antibodies, such as easier synthesis, cost-effective production, and enhanced binding affinity, making them highly attractive for diagnostic, therapeutic, and research applications.

Restraints in the Global Aptamers Market

Intellectual property (IP) issues pose significant challenges to the growth of the aptamers market. Patent rights and licensing agreements for aptamers and their associated technologies can restrict the commercialization potential for specific applications or targets. The complex IP landscape related to aptamer-based technologies can create legal uncertainties and obstacles for market participants. These IP complexities may impede market progress by making it difficult for companies to navigate patent claims and secure necessary licenses. Consequently, such legal barriers can limit the opportunities for innovation and expansion within the aptamers sector.

Market Trends of the Global Aptamers Market

SELEX (Systematic Evolution of Ligands by Exponential Enrichment) remains the leading technique for selecting aptamers. To boost efficiency, lower costs, and enhance the quality of aptamers, there is an increasing emphasis on optimizing and automating the SELEX process. Recent advancements in high-throughput screening, microfluidics, and robotics are being utilized to refine the aptamer development workflow, making it more efficient and scalable. These technological improvements aim to streamline the SELEX process, facilitating better and faster production of aptamers. By integrating these innovations, the process becomes more accessible and adaptable, addressing previous limitations and expanding the potential for aptamer applications.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Technology Analysis
• Value Chain Analysis
• Patent Analysis

Aptamers Market, By Type

• Market Overview
• DNA Aptamers
• XNA Aptamers
• RNA Aptamers

Aptamers Market, By Technology

• Market Overview
• SELEX
• Other Technologies

Aptamers Market, By Application

• Market Overview
• Therapeutics Development
• Research & Development
• Diagnostics
• Other Applications

Aptamers Market, By End User

• Market Overview
• Pharmaceutical & Biotechnology Companies
• Academic & Government Research Institutes
• Contract Research Organizations
• Other End Users

Aptamers Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Aptamer Group (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Raptamer Discovery Group (US)
  • S Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• omalogic, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aptamer Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aptagen, LLC (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Maravai Lifesciences (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kaneka Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neoventures Biotechnology Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aptus Biotech (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Base Pair Biotechnologies (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amsbio (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novaptech (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Techne (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aptitude Medical Systems (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Raybiotech, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alpha Diagnostic International, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Creative Biolabs (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Creative Biogene (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vivonics Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iba Lifesciences GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aptabharat Innovations Pvt. Ltd (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Profacgen (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mediven (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pure Biologics SA (Poland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oak Biosciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments